Kopran Ltd. (BSE: 524280) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,356 Cr, it ranks #1,434 by market cap among the 6,197 Indian listed companies on FinBizNet, and #42 of 86 in Medicinal Chemicals and Botanical Products. At ₹288.43 (as of 16 Nov 2026), the share price is 2.5% below its 52-week high of ₹295.83 and 167.0% above its 52-week low of ₹108.04. The share price is up 82.4% over one year and up 59.6% over three months.
| Current Price | ₹288.43 |
|---|---|
| Market Cap | ₹1,356 Cr |
| BSE Code | 524280 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 52.4 |
| Return on Equity | 4.91% |
| Return on Assets | 4.31% |
| 52-Week Range | ₹108.04 – ₹295.83 |
| 1-Year Price Change | +82.4% |
| 3-Month Price Change | +59.6% |
| Beta (1Y) | 1.07 |
| Dividend Yield | 1.08% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.kopran.com |
| Revenue | ₹211 Cr |
|---|---|
| Net Profit | ₹4 Cr |
| Net Margin | 2.1% |
| EPS (Basic) | ₹0.91 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kopran Ltd. reported revenue of ₹211 Cr in Q2 FY27, up 79.2% from ₹118 Cr in Q2 FY26 and up 37.2% from ₹154 Cr in Q1 FY27. It posted a net profit of ₹4 Cr for the quarter, against a net loss of ₹10 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹118 Cr (Q2 FY26) to ₹234 Cr (Q4 FY26). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹211 Cr | ₹4 Cr | 2.1% |
| Q1 FY27 | ₹154 Cr | ₹7 Cr | 4.4% |
| Q4 FY26 | ₹234 Cr | ₹19 Cr | 8.1% |
| Q3 FY26 | ₹194 Cr | ₹9 Cr | 4.8% |
| Q2 FY26 | ₹118 Cr | −₹10 Cr | −8.4% |
| Q1 FY26 | ₹135 Cr | ₹7 Cr | 5.5% |
| Q4 FY25 | ₹172 Cr | ₹10 Cr | 5.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 41.82% of Kopran Ltd.'s shares as of Sept 2026, against 44.42% in Sept 2025 (−2.60 percentage points). Delivery averaged 38.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company offers drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
1. Pharmaceuticals Business-This segment engages in the manufacture and sale of finished dosage forms and active pharmaceutical ingredients. 2. Consumer Care-This segment consumer healthcare products, which include family toothpaste under the SPARKLE brand; body deodorants and deo talcs; and face moisturizers and face wash products. 3. OTC Products-0 4. Trading Products-This segment manufactures and sells over-the-counter products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Kopran Ltd. | ₹1,356 Cr | 52.4 | 4.91% | ₹211 Cr | +82.4% |
Listed by market capitalisation. Ratios are shown for context only.
Kopran Ltd. is trading at ₹288.43, with a market capitalisation of ₹1,356 Cr.
Kopran Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kopran Ltd. has a P/E of 52.4 and a return on equity of 4.91%.
Kopran Ltd. is listed on the BSE under the scrip code 524280.
Kopran Ltd.'s share price is up 82.4% over one year and up 59.6% over three months. Its 52-week range is ₹108.04 to ₹295.83.
In Q2 FY27, Kopran Ltd. reported revenue of ₹211 Cr and net profit of ₹4 Cr, with basic EPS of ₹0.91 (consolidated, parsed from the company's exchange filing).
Kopran Ltd. reported revenue of ₹211 Cr in Q2 FY27, up 79.2% from ₹118 Cr in Q2 FY26 and up 37.2% from ₹154 Cr in Q1 FY27.
Promoters held 41.82% of Kopran Ltd.'s shares as of Sept 2026, against 44.42% in Sept 2025 (−2.60 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.